IE51744B1 - New products prepared from the serum thymic factor or its analogues and derivatives,process for preparing these products,the use of these products as medicaments,tracers obtained from these products and the use of these tracers in detection processes - Google Patents
New products prepared from the serum thymic factor or its analogues and derivatives,process for preparing these products,the use of these products as medicaments,tracers obtained from these products and the use of these tracers in detection processesInfo
- Publication number
- IE51744B1 IE51744B1 IE113581A IE113581A IE51744B1 IE 51744 B1 IE51744 B1 IE 51744B1 IE 113581 A IE113581 A IE 113581A IE 113581 A IE113581 A IE 113581A IE 51744 B1 IE51744 B1 IE 51744B1
- Authority
- IE
- Ireland
- Prior art keywords
- stf
- metal
- product
- fraction
- derivative
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 42
- 230000008569 process Effects 0.000 title claims abstract description 31
- 108010003422 Circulating Thymic Factor Proteins 0.000 title claims description 154
- 239000003814 drug Substances 0.000 title claims description 5
- 238000004519 manufacturing process Methods 0.000 title abstract description 4
- 238000001514 detection method Methods 0.000 title description 10
- 229910052751 metal Inorganic materials 0.000 claims abstract description 67
- 239000002184 metal Substances 0.000 claims abstract description 67
- 230000002992 thymic effect Effects 0.000 claims abstract description 18
- 239000000126 substance Substances 0.000 claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 239000011701 zinc Substances 0.000 claims description 42
- 230000000694 effects Effects 0.000 claims description 39
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 30
- 210000002966 serum Anatomy 0.000 claims description 30
- 229910052725 zinc Inorganic materials 0.000 claims description 30
- 239000000700 radioactive tracer Substances 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 17
- 238000011534 incubation Methods 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 150000002739 metals Chemical class 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 230000002860 competitive effect Effects 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000004696 coordination complex Chemical class 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 description 30
- 230000003213 activating effect Effects 0.000 description 27
- 238000001727 in vivo Methods 0.000 description 25
- 230000004071 biological effect Effects 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 18
- 210000000952 spleen Anatomy 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 14
- 229960002170 azathioprine Drugs 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 13
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 13
- 229920001429 chelating resin Polymers 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 235000005074 zinc chloride Nutrition 0.000 description 7
- 239000011592 zinc chloride Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 5
- 229940105329 carboxymethylcellulose Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 4
- 229910000368 zinc sulfate Inorganic materials 0.000 description 4
- 229960001763 zinc sulfate Drugs 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004411 aluminium Substances 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- QKZLCNQUIQIPOW-QQCJEOGWSA-N (2s)-4-amino-2-[[(2s)-2-[[2-[[2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-aminopropanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoic acid Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O QKZLCNQUIQIPOW-QQCJEOGWSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- JLDSOYXADOWAKB-UHFFFAOYSA-N aluminium nitrate Chemical compound [Al+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O JLDSOYXADOWAKB-UHFFFAOYSA-N 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001173 tumoral effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YIJVJUARZXCJJP-WHFBIAKZSA-N (2s)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCC(=O)N1 YIJVJUARZXCJJP-WHFBIAKZSA-N 0.000 description 1
- LIFNDDBLJFPEAN-BPSSIEEOSA-N (2s)-4-amino-2-[[(2s)-2-[[2-[[2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H]1CCC(=O)N1 LIFNDDBLJFPEAN-BPSSIEEOSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- OFSWLWKRSFEGQA-UHFFFAOYSA-N 6-amino-2-[2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoylamino]hexanoic acid Chemical compound NCCCCC(C(O)=O)NC(=O)C(C)NC(=O)C1CCC(=O)N1 OFSWLWKRSFEGQA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101000921522 Bos taurus Cytochrome c Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- JJKKWYQVHRUSDG-GUBZILKMSA-N Glu-Ala-Lys Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O JJKKWYQVHRUSDG-GUBZILKMSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 101000766234 Salmo salar Serotransferrin-1 Proteins 0.000 description 1
- 241000277284 Salvelinus fontinalis Species 0.000 description 1
- 101710185318 Thymic factor Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- 238000000559 atomic spectroscopy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000001538 myasthenic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000724 thymus hormone Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- -1 zinc Chemical class 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C07K7/062—Serum thymic factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8017027 | 1980-05-22 | ||
| GB8030507 | 1980-09-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE811135L IE811135L (en) | 1981-11-22 |
| IE51744B1 true IE51744B1 (en) | 1987-03-18 |
Family
ID=26275622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE113581A IE51744B1 (en) | 1980-05-22 | 1981-05-21 | New products prepared from the serum thymic factor or its analogues and derivatives,process for preparing these products,the use of these products as medicaments,tracers obtained from these products and the use of these tracers in detection processes |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0041019B1 (enrdf_load_stackoverflow) |
| AU (1) | AU553640B2 (enrdf_load_stackoverflow) |
| CA (1) | CA1170991A (enrdf_load_stackoverflow) |
| DE (1) | DE3166925D1 (enrdf_load_stackoverflow) |
| DK (1) | DK221681A (enrdf_load_stackoverflow) |
| ES (2) | ES8306022A1 (enrdf_load_stackoverflow) |
| GR (1) | GR75636B (enrdf_load_stackoverflow) |
| IE (1) | IE51744B1 (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7309690B2 (en) | 2001-10-09 | 2007-12-18 | Centre National De La Recherche Scientifique | Use of thymulin-like peptides for making pain-relieving medicines |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634682A (en) * | 1982-11-30 | 1987-01-06 | Sloan-Kettering Institute For Cancer | Radioimmunoassays for the serum thymic factor (FTS) |
| CS256897B1 (en) * | 1984-12-17 | 1988-04-15 | Evzen Kasafirek | Series thymic factor's analogue-type peptides |
| IT1188550B (it) * | 1986-02-07 | 1988-01-14 | Sclavo Spa | Peptide sintetico ad attivita' interleukina 1 umana |
| WO2007108848A1 (en) | 2006-03-20 | 2007-09-27 | Smith & Nephew, Inc. | Acetabular cup assembly for multiple bearing materials |
| FR2930156B1 (fr) * | 2008-04-21 | 2011-10-28 | Cll Pharma | Utilisation du nonapeptide pat dans le traitement des maladies autoimmunes. |
| WO2021030689A2 (en) * | 2019-08-15 | 2021-02-18 | Cytolyf Therapeutics Llc | Zinc activated thymulin and methods of preparation and administration |
-
1981
- 1981-05-20 GR GR65000A patent/GR75636B/el unknown
- 1981-05-20 DK DK221681A patent/DK221681A/da not_active Application Discontinuation
- 1981-05-21 AU AU70905/81A patent/AU553640B2/en not_active Ceased
- 1981-05-21 DE DE8181400807T patent/DE3166925D1/de not_active Expired
- 1981-05-21 IE IE113581A patent/IE51744B1/en not_active IP Right Cessation
- 1981-05-21 CA CA000378037A patent/CA1170991A/en not_active Expired
- 1981-05-21 EP EP19810400807 patent/EP0041019B1/fr not_active Expired
- 1981-05-22 ES ES502911A patent/ES8306022A1/es not_active Expired
-
1982
- 1982-12-16 ES ES518298A patent/ES518298A0/es active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7309690B2 (en) | 2001-10-09 | 2007-12-18 | Centre National De La Recherche Scientifique | Use of thymulin-like peptides for making pain-relieving medicines |
Also Published As
| Publication number | Publication date |
|---|---|
| GR75636B (enrdf_load_stackoverflow) | 1984-08-02 |
| EP0041019A3 (en) | 1982-03-10 |
| ES502911A0 (es) | 1983-05-01 |
| DK221681A (da) | 1981-11-23 |
| EP0041019B1 (fr) | 1984-10-31 |
| AU553640B2 (en) | 1986-07-24 |
| IE811135L (en) | 1981-11-22 |
| AU7090581A (en) | 1981-11-26 |
| ES8501628A1 (es) | 1984-12-16 |
| EP0041019A2 (fr) | 1981-12-02 |
| CA1170991A (en) | 1984-07-17 |
| DE3166925D1 (en) | 1984-12-06 |
| ES8306022A1 (es) | 1983-05-01 |
| ES518298A0 (es) | 1984-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Powell et al. | Radioimmunoassay for substance P | |
| Muller et al. | Cholecystokinin and its COOH-terminal octapeptide in the pig brain. | |
| LESNIAK et al. | Human growth hormone radioreceptor assay using cultured human lymphocytes | |
| Carraway et al. | Radioimmunoassay for neurotensin, a hypothalamic peptide. | |
| JPH06501938A (ja) | ペプチドよりなるｈｉｖ複製阻害剤 | |
| US4680276A (en) | Metal polypeptides | |
| IE51744B1 (en) | New products prepared from the serum thymic factor or its analogues and derivatives,process for preparing these products,the use of these products as medicaments,tracers obtained from these products and the use of these tracers in detection processes | |
| Dietrich | The immune response to heterologous red cells in mice | |
| US5616685A (en) | snRNP-A antigen and fragments thereof | |
| AU606595B2 (en) | HTLV-III/LAV virus related peptides, antibodies to the peptides, vaccines, passive and active immunization against AIDS virus and diagnostic test for the serological detection of the AIDS virus | |
| EP0055113B1 (en) | Deca- undeca- dodeca- and tridecapeptides with thymic activity, method for their preparation and compositions containing them | |
| Praissman et al. | Modification of the C-terminal octapeptide of cholecystokinin with a high-specific-activity lodinated imidoester: Preparation, characterization, and binding to isolated pancreatic acinar cells | |
| Cebra et al. | Structure of heavy chain from strain 13 guinea pig immunoglobulin-G (2). I. Isolation of cyanogen bromide fragments | |
| EP0082789B1 (en) | Immunological composition and method for hepatitis b virus | |
| US4778784A (en) | Cyclic peptide and method of use for inducing an immunological response to hepatitis B virus | |
| RU2120944C1 (ru) | [(s) pmp1, d-trp2, pen6, arg8]окситоцин | |
| Lai et al. | Primary structure of cholera toxin subunit A1: isolation, partial sequences and alignment of the BrCN fragments | |
| EP0492478B1 (en) | Tert-butyloxycarbonyl-L-tyrosyl-peptidoglycan monomer and 125 I-labelled derivative thereof, their preparation and use | |
| US6187810B1 (en) | Macrocyclic compounds made from suboxide units | |
| Kopp et al. | Specific Antibodies against α‐Melanotropin for Radioimmunoassay: Parallelism between the Immunochemical Cross‐Reactions of Melanotropin Structural Analogues and Their Biological Activity | |
| Trischmann et al. | Primary structure of the CH3 homology region from guinea pig IgG2 antibodies | |
| Harcourt et al. | Detection of α-subunit isoforms in human muscle acetylcholine receptor by specific T cells from a myasthenia gravis patient | |
| Woodhead et al. | The immunological properties of porcine parathyroid hormone | |
| Jeejeebhoy et al. | On the use of tritium-labelled albumin for studies of intestinal absorption | |
| CA1177394A (en) | Endorphins having placental or pancreatic origin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |